Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment

Nature Reviews Urology, Published online: 16 March 2023; doi:10.1038/s41585-023-00747-wIn this Review, Nolla and colleagues discuss the use of patient-reported outcome measures (PROMs) to assess health-related quality of life in six immunotherapy versus sunitinib clinical trials for advanced renal cell carcinoma and, following this discussion, make recommendations for future PROM use in clinical trials.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research